Changes in Utilization and Discard of Hepatitis C–Infected Donor Livers in the Recent Era
Top Cited Papers
Open Access
- 26 July 2016
- journal article
- research article
- Published by Elsevier BV in American Journal of Transplantation
- Vol. 17 (2), 519-527
- https://doi.org/10.1111/ajt.13976
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (K24DK101828, F30DK095545)
- National Institute of Allergy and Infectious Diseases (K24DA034621)
- National Cancer Institute (K23CA177321)
This publication has 30 references indexed in Scilit:
- Sofosbuvir‐based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantationLiver Transplantation, 2016
- Interferon‐free therapy for genotype 1 hepatitis C in liver transplant recipients: Real‐world experience from the hepatitis C therapeutic registry and research networkLiver Transplantation, 2015
- OPTN/SRTR 2013 Annual Data Report: LiverAmerican Journal of Transplantation, 2015
- Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantationJournal of Hepatology, 2014
- Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantationLiver Transplantation, 2013
- Projected future increase in aging hepatitis C virus–infected liver transplant candidates: A potential effect of hepatocellular carcinomaLiver Transplantation, 2012
- Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determinedTransplant International, 2012
- Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysisTransplant International, 2010
- Effective communication of standard errors and confidence intervalsBiostatistics, 2008
- What determines the natural history of recurrent hepatitis C after liver transplantation?Journal of Hepatology, 2005